Literature DB >> 21162693

Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Jian-Ping Zhang1, Anil K Malhotra.   

Abstract

IMPORTANCE OF THE FIELD: Antipsychotic drug is the mainstay of treatment for schizophrenia, and there are large inter-individual differences in clinical response and side effects. Pharmacogenetics provides a valuable tool to fulfill the promise of personalized medicine by tailoring treatment based on one's genetic markers. AREAS COVERED IN THIS REVIEW: This article reviews the pharmacogenetic literature from early 1990s to 2010, focusing on two aspects of drug action: pharmacokinetics and pharmacodynamics. Genetic variants in the neurotransmitter receptors including dopamine and 5-HT and metabolic pathways of drugs including CYP2D6 and COMT were discussed in association with clinical drug response and side effects. WHAT THE READER WILL GAIN: Readers are expected to learn the up-to-date evidence in pharmacogenetic research and to gain familiarity to the issues and challenges facing the field. TAKE HOME MESSAGE: Pharmacogenetic research of antipsychotic drugs is both promising and challenging. There is consistent evidence that some genetic variants can affect clinical response and side effects. However, more studies that are designed specifically to test pharmacogenetic hypotheses are clearly needed to advance the field.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21162693      PMCID: PMC3057913          DOI: 10.1517/17425255.2011.532787

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  198 in total

1.  -759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain.

Authors:  Shih-Jen Tsai; Chen-Jee Hong; Younger W-Y Yu; Ching-Hua Lin
Journal:  Lancet       Date:  2002-11-30       Impact factor: 79.321

2.  -759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment.

Authors:  Seunghyong Ryu; Eun Young Cho; Taesung Park; Sohee Oh; Won-Seok Jang; Shin-Kyum Kim; Dongsoo Lee; Kyung Sue Hong
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-01-12       Impact factor: 5.067

3.  The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response.

Authors:  A K Malhotra; D Goldman; R W Buchanan; W Rooney; A Clifton; M H Kosmidis; A Breier; D Pickar
Journal:  Mol Psychiatry       Date:  1998-01       Impact factor: 15.992

4.  Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia.

Authors:  R H Segman; U Heresco-Levy; B Finkel; T Goltser; R Shalem; M Schlafman; A Dorevitch; A Yakir; D Greenberg; A Lerner; B Lerer
Journal:  Mol Psychiatry       Date:  2001-03       Impact factor: 15.992

5.  Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations.

Authors:  Rudi Hwang; Takahiro Shinkai; Vincenzo De Luca; Daniel J Müller; Xingqun Ni; Fabio Macciardi; Steven Potkin; Jeffrey A Lieberman; Herbert Y Meltzer; James L Kennedy
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

6.  Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia.

Authors:  Chima Matsumoto; Osamu Ohmori; Takahiro Shinkai; Hiroko Hori; Jun Nakamura
Journal:  Psychiatr Genet       Date:  2004-12       Impact factor: 2.458

7.  Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia.

Authors:  S Volpi; C Heaton; K Mack; J B Hamilton; R Lannan; C D Wolfgang; L Licamele; M H Polymeropoulos; C Lavedan
Journal:  Mol Psychiatry       Date:  2008-06-03       Impact factor: 15.992

Review 8.  Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis.

Authors:  Diederik E Tenback; Peter N van Harten; Jim van Os
Journal:  Mov Disord       Date:  2009-12-15       Impact factor: 10.338

9.  Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism.

Authors:  Bernard Lerer; Ronnen H Segman; Heiner Fangerau; Ann K Daly; Vincenzo S Basile; Roberto Cavallaro; Harald N Aschauer; Robin G McCreadie; Stephanie Ohlraun; Nicol Ferrier; Mario Masellis; Massimiliano Verga; Joachim Scharfetter; Marcella Rietschel; Roger Lovlie; Uriel Heresco Levy; Herbert Y Meltzer; James L Kennedy; Vidar M Steen; Fabio Macciardi
Journal:  Neuropsychopharmacology       Date:  2002-07       Impact factor: 7.853

10.  Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population.

Authors:  Neetha N Vijayan; Sujatha Bhaskaran; Linda V Koshy; Chandrasekhar Natarajan; Lekshmy Srinivas; Chandrasekharan M Nair; Priya M Allencherry; Moinak Banerjee
Journal:  Behav Brain Funct       Date:  2007-07-25       Impact factor: 3.759

View more
  61 in total

Review 1.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome.

Authors:  Michael Camilleri; David A Katzka
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

Review 2.  The role of pharmacogenetics in nonmalignant gastrointestinal diseases.

Authors:  Michael Camilleri
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-07       Impact factor: 46.802

3.  Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach.

Authors:  Douglas M Ruderfer; Alexander W Charney; Ben Readhead; Brian A Kidd; Anna K Kähler; Paul J Kenny; Michael J Keiser; Jennifer L Moran; Christina M Hultman; Stuart A Scott; Patrick F Sullivan; Shaun M Purcell; Joel T Dudley; Pamela Sklar
Journal:  Lancet Psychiatry       Date:  2016-02-23       Impact factor: 27.083

Review 4.  Pharmacogenetics of antipsychotics.

Authors:  Eva J Brandl; James L Kennedy; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

5.  Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype.

Authors:  Yi Zhang; Meijuan Chen; Jun Chen; Zhiguo Wu; Shunying Yu; Yiru Fang; Chen Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-01-22       Impact factor: 4.530

6.  Genetics of schizophrenia: What do we know?

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Curr Psychiatr       Date:  2013-03-01

Review 7.  Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.

Authors:  Gavin P Reynolds; Olga O McGowan; Caroline F Dalton
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 8.  Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.

Authors:  Katarzyna Drozda; Daniel J Müller; Jeffrey R Bishop
Journal:  Pharmacotherapy       Date:  2014-02       Impact factor: 4.705

9.  Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population.

Authors:  Q Xu; X Wu; M Li; H Huang; C Minica; Z Yi; G Wang; L Shen; Q Xing; Y Shi; L He; S Qin
Journal:  Pharmacogenomics J       Date:  2015-08-18       Impact factor: 3.550

10.  Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.

Authors:  Jian-Ping Zhang; Delbert G Robinson; Juan A Gallego; Majnu John; Jin Yu; Jean Addington; Mauricio Tohen; John M Kane; Anil K Malhotra; Todd Lencz
Journal:  Schizophr Bull       Date:  2015-08-28       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.